ARDX Ardelyx Inc.

4.74
-0.14  -3%
Previous Close 4.88
Open 4.88
Price To Book 4.35
Market Cap 297,676,119
Shares 62,800,869
Volume 189,062
Short Ratio
Av. Daily Volume 1,177,778

NewsSee all news

  1. Ardelyx to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    FREMONT, Calif., Sept. 17, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with

  2. Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation

    FREMONT, Calif., Sept. 12, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with

  3. Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment

    FREMONT, Calif., Sept. 3, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal

  4. Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study

    FREMONT, Calif., Sept. 2, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA approval announced September 12, 2019.
Tenapanor (T3MPO-2)
Constipation-predominant irritable bowel syndrome (IBS-C)
Onset of action trial data released November 21, 2017 - noted significantly reduced serum potassium in patients. Development to be discontinued.
RDX7675
Hyperkalemia
Phase 3 data due 4Q 2019.
Tenapanor - PHREEDOM
Hyperphosphatemia in end-stage renal disease (ESRD) patients
Phase 3 data released May 12, 2017. Primary endpoint met - however, competitive concerns raised.
Tenapanor (T3MPO-1)
Constipation-predominant irritable bowel syndrome (IBS-C)
Phase 3 trial met primary endpoint.
Tenapanor - AMPLIFY
Hyperphosphatemia - adjunctive therapy to phosphate binders

Latest News

  1. Ardelyx to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    FREMONT, Calif., Sept. 17, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with

  2. Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation

    FREMONT, Calif., Sept. 12, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with

  3. Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment

    FREMONT, Calif., Sept. 3, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal

  4. Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study

    FREMONT, Calif., Sept. 2, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ:ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal